0.41
-0.0536(-11.61%)
Currency In USD
| Previous Close | 0.46 |
| Open | 0.47 |
| Day High | 0.46 |
| Day Low | 0.36 |
| 52-Week High | 3.42 |
| 52-Week Low | 0.22 |
| Volume | 39.72M |
| Average Volume | 11.53M |
| Market Cap | 18.81M |
| PE | -0.65 |
| EPS | -0.63 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.96 |
| Change | -0.05 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.15 as of June 06, 2025 at a share price of $0.408. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $34.58 as of June 06, 2025 at a share price of $0.408.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the ent
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
GlobeNewswire Inc.
Jun 04, 2025 12:05 PM GMT
Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for Fast-Track, Conditional Marketing Authorization, A
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
GlobeNewswire Inc.
May 07, 2025 12:05 PM GMT
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today